iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

by Business Wire • 2025/02/05 • 0 Comments

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company advancing IVMED-85 for the treatment of pediatric myopia, today announced that it has closed its fully subscribed Series B-2 financing of $3 million. This investment will support iVeena’s pursuit of advancing their innovative pediatric myopia program. All IND-enabling studies are well underway supporting a targeted IND submission in H1-2025. “We are pleased to welcome Dr. Jerry Hu to our Board

← Avian Influenza Landscape in the US

Qlaris Bio Announces Positive Topline Data From Two Phase II Trials of QLS-111 in Patients With Primary Open Angle Glaucoma and Ocular Hypertension →

Post navigation